Skip to content
  • Home
  • News
  • Videos
  • Conference Coverage
  • Podcasts
  • Resource Centers
    • Acne
    • Skin Cancer
    • Alopecia
    • Atopic Dermatitis
    • Cosmetics
    • Hidradenitis Suppurativa (HS)
    • Pediatrics
    • Pigment Disorders
    • Practice Management
    • Psoriasis
    • Rare Diseases
    • Rosacea
    • Vitiligo
  • Home
  • News
  • Videos
  • Conference Coverage
  • Podcasts
  • Resource Centers
    • Acne
    • Skin Cancer
    • Alopecia
    • Atopic Dermatitis
    • Cosmetics
    • Hidradenitis Suppurativa (HS)
    • Pediatrics
    • Pigment Disorders
    • Practice Management
    • Psoriasis
    • Rare Diseases
    • Rosacea
    • Vitiligo
Subscribe

Inside the AD Pipeline: Zai Lab’s Long-acting ZL-1503 Shows Promise in First-in-human Study

One dose of ZL-1503, a long-acting interleukin (IL)-13/IL-31 receptor alpha (Rα) bispecific antibody, produced near-complete inhibition of IL-13-stimulated pSTAT6 in healthy volunteers for at least three months across dose levels, according to first-in-human results from the single-ascending-dose portion of a Phase 1/1b trial.

Next →

The Dermatology Digest is an independent, multi-channel resource for practicing dermatologists and dermatological practitioners.

Quick Links
  • Advertise with Us
  • About Us
  • Advertise with Us
  • About Us
Follow us
Linkedin Facebook-f X-twitter Youtube

© 2026 All Rights Reserved.